Researchers discover new non-invasive method for diagnosing epilepsy

Brain scans of test patients using new technology and methods show that the frontal lobe of the brain is most involved in severe seizures.

(Medical Xpress)—A team of University of Minnesota biomedical engineers and researchers from Mayo Clinic published a groundbreaking study today that outlines how a new type of non-invasive brain scan taken immediately after a seizure gives additional insight into possible causes and treatments for epilepsy patients. The new findings could specifically benefit millions of people who are unable to control their epilepsy with medication.

The research was published online today in BRAIN, a leading international journal of neurology.

The study's findings include:

  • Important data about can be gathered through non-invasive methods, not only during a seizure, but immediately after a seizure.
  • The frontal lobe of the brain is most involved in severe .
  • Seizures in the are most common among adults. The new technique used in the study will help determine the side of the brain where the seizures originate.
This video is not supported by your browser at this time.
Bin He, a biomedical engineering professor in the University of Minnesota�s College of Science and Engineering and senior author of the study, discusses his research on a new type of non-invasive brain scan that gives additional insight into possible causes and treatments for epilepsy patients. Credit: Copyright 2012 Regents of the University of Minnesota. All rights reserved. Animation courtesy of the Mayo Clinic.

"This is the first-ever study where new non-invasive methods were used to study patients after a seizure instead of during a seizure," said Bin He, a biomedical engineering professor in the University of Minnesota's College of Science and Engineering and senior author of the study. "It's really a for research in ."

Epilepsy affects nearly 3 million Americans and 50 million people worldwide. While medications and other treatments help many people of all ages who live with epilepsy, about 1 million people in the U.S. and 17 million people worldwide continue to have seizures that can severely limit their lives.

The biggest challenge for researchers is to locate the part of the brain responsible for the seizures to determine possible treatments. In the past, most research has focused on studying patients while they were having a seizure, or what is technically known as the "ictal" phase of a seizure. Some of these studies involved such as surgery to collect data.

In the new study, researchers from the University of Minnesota and Mayo Clinic used a novel approach by studying the brains of 28 patients immediately after seizures, or what is technically know as the "postictal" phase of a seizure. They used a specialized type of non-invasive EEG with 76 electrodes attached to the scalp for gathering data in contrast to most previous research that used 32 electrodes. The researchers used specialized imaging technology to gather data about the patient. The findings may lead to innovative means of locating the regions responsible for seizures in individual patients using non-invasive strategies.

"The imaging technology that we developed here at the University of Minnesota allowed us to tackle this research and gather several thousand data points that helped us determine our findings," He said. "The technical innovation was a big part of what helped us make this discovery."

He, who was recently appointed the director of the University of Minnesota's Institute for Engineering in Medicine, said this study was also a good example of a true partnership between engineering and medicine to further medical research.

"The innovations in engineering combined with collaborations with clinicians at Mayo Clinic made this research a reality," He said.

Related Stories

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.